This study is for people aged 40 to 85 with Chronic Obstructive Pulmonary Disease (COPD), a lung condition that makes breathing hard. The study tests a drug called dupilumab, given as a shot under the skin, to see if it helps reduce lung inflammation, which is swelling and irritation in the lungs. It compares dupilumab to a placebo, a treatment with no active drug. The study will last up to 40 weeks, with 24 weeks of treatment and 9 visits to the study center.

• The study lasts up to 40 weeks with 9 visits required.
• Participants will receive either dupilumab or a placebo.
• Dupilumab aims to help improve lung function and life quality.

To join, you must have a doctor-diagnosed COPD, be a current or former smoker, and meet specific health criteria. You can't join if you have asthma, other lung diseases, or have been on certain treatments recently. This study helps researchers understand if dupilumab is effective for people with COPD. Always talk to your doctor before enrolling in a study.